Sarepta Therapeutics Inc. (SRPT) Rating Reiterated by William Blair
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating restated by investment analysts at William Blair in a research report issued to clients and investors on Sunday. They currently have a $88.00 target price on the stock. William Blair’s price objective indicates a potential upside of 43.30% from the company’s current price.
Several other research firms have also commented on SRPT. RBC Capital Markets upgraded Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating in a research note on Monday, September 19th. Needham & Company LLC upped their target price on Sarepta Therapeutics from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, July 22nd. WBB Securities reiterated a “strong-buy” rating and issued a $60.00 target price (up from $40.00) on shares of Sarepta Therapeutics in a research note on Tuesday, September 20th. Robert W. Baird reiterated an “outperform” rating and issued a $102.00 target price on shares of Sarepta Therapeutics in a research note on Friday. Finally, Oppenheimer Holdings Inc. upped their target price on Sarepta Therapeutics from $60.00 to $76.00 in a research note on Monday, September 19th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $54.44.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 61.41 on Friday. The stock’s market capitalization is $2.94 billion. The stock’s 50 day moving average price is $35.91 and its 200-day moving average price is $23.83. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $63.73.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same period in the prior year, the business earned ($0.87) earnings per share. Analysts expect that Sarepta Therapeutics will post ($4.16) earnings per share for the current year.
In other news, SVP David T. Howton sold 9,304 shares of the stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $50.00, for a total transaction of $465,200.00. Following the sale, the senior vice president now directly owns 11,168 shares in the company, valued at approximately $558,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Edward M. Md Kaye sold 40,179 shares of the stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total value of $2,410,740.00. Following the sale, the chief executive officer now owns 117,162 shares in the company, valued at $7,029,720. The disclosure for this sale can be found here. Insiders own 10.90% of the company’s stock.
Several hedge funds have recently made changes to their positions in SRPT. Vanguard Group Inc. boosted its stake in shares of Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock worth $59,227,000 after buying an additional 161,790 shares during the last quarter. State Street Corp boosted its stake in shares of Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock worth $58,976,000 after buying an additional 625,051 shares during the last quarter. BlackRock Fund Advisors boosted its stake in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock worth $20,865,000 after buying an additional 25,799 shares during the last quarter. Finally, Franklin Resources Inc. bought a new stake in shares of Sarepta Therapeutics during the first quarter worth $13,506,000. Institutional investors and hedge funds own 72.09% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.